Emerging Markets Earnings Roundup: Sanofi (Part 10)
This article was originally published in PharmAsia News
Executive Summary
Sanofi CEO Christopher Viehbacher gave analysts a rundown on emerging markets and the scope for the Sanofi Pasteur business along with a pipeline of biologic products that has led the company to ramp up marketing and data gathering.
You may also be interested in...
Sanofi Says Vaccines Getting Back On Track, Rejects M&A
The company has addressed its vaccine manufacturing issues and is about to resubmit MS therapy Lemtrada to FDA; it reported a 4.7% sales increase in the first quarter, driven by growth in its diabetes and consumer health divisions and Genzyme.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.